---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-037314"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2022-03-24T23:59:59+00:00"
generated_at: "2026-06-26T18:51:30.278718+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Avista SPAC to combine with OmniAb (Ligand antibody business) at $850M pre-money value

## Summary
- OmniAb valued at $850M pre-money; earnout of up to 15M shares with $12.50/$15.00 VWAP targets.
- Sponsor to purchase $15M in APAC common + warrants via Forward Purchase, backstop up to $100M for redemptions.
- Transaction includes Distribution of OmniAb stock to Ligand shareholders immediately prior to Merger.
- Post-closing APAC will redomicile to Delaware and list on Nasdaq under 'OABI' (warrants 'OABIW').
- Conditions include HSR clearance, APAC shareholder approval, Nasdaq listing, and net tangible assets ≥$5M.

## SEC filing metadata
- accession: 0001104659-22-037314
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2022-03-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000110465922037314/0001104659-22-037314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000110465922037314/tm2210239d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-037314
- JSON: https://secwatch.observer/filing/0001104659-22-037314.json
- Plain text: https://secwatch.observer/filing/0001104659-22-037314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.